ICPT Intercept Pharmaceuticals Inc.

118.46
+7.64  (+7%)
Previous Close 110.82
Open 131.67
Price To Book 36.67
Market Cap 3512868279
Shares 29,654,468
Volume 3,980,458
Short Ratio
Av. Daily Volume 536,684

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrolment to be completed in 2019.
Ocaliva - Obeticholic acid (OCA) - REVERSE
NASH patients with compensated cirrhosis
Phase 2 primary endpoint met - July 31, 2017. One patient death noted but DSMB noted unlikely to be related to OCA (company unsure).
Obeticholic acid (OCA) - CONTROL
NASH patients taking statins
Approved May 27 2016. Updated U.S. label for Ocaliva anticipated by early 2018
Obeticholic acid (Ocaliva)
Primary biliary cirrhosis (PBC) - POISE
Phase 3 data due 1Q 2019.
Ocaliva (Obeticholic acid (OCA)) - REGENERATE
Adult nonalcoholic steatohepatitis (NASH) patients.
Phase 2 data released July 31, 2017 - primary endpoint met. Late breaker at AASLD October 23, 2017.
Obeticholic acid (OCA) AESOP
Primary Sclerosing Cholangitis (PSC)

Latest News

  1. Why Intercept Pharmaceuticals Stock Is Soaring Today
  2. Intercept Comes in First With Liver Drug, But Race Isn’t Over
  3. Shares of Intercept Pharmaceuticals Rise Sharply on Drug Trial Results
  4. After Gilead Failed, Intercept Stock Rises On NASH Treatment Study
  5. Intercept Pharmaceuticals up 14% after positive NASH trial results
  6. US STOCKS-Wall St set to open lower as U.S.-China trade talks resume
  7. Intercept Announces Positive Topline Results from Pivotal Phase 3 REGENERATE Study of Obeticholic Acid in Patients with Liver Fibrosis Due to NASH
  8. Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
  9. Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure
  10. Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails
  11. Is Intercept Pharmaceuticals a Buy?
  12. See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
  13. Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  14. Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Moderna
  15. JMP Upgrades Intercept Pharma Ahead Of NASH Trial Data
  16. The Biggest Biotech Binary Event in 2019 Is Just Around the Corner
  17. NASH Space in Focus in 2019 as Firms Look to Diversify
  18. Are Options Traders Betting on a Big Move in Intercept Pharmaceuticals (ICPT) Stock?